Anti-angiogenesis therapy in colorectal cancer

Abstract

Herbert I Hurwitz speaks to Laura Dormer, Commissioning Editor: Herbert I Hurwitz is Associate Professor of Medicine at Duke University Medical Center in Durham (NC, USA). Dr Hurwitz completed his medical training at Thomas Jefferson University (PA, USA) and began his career with a residency in Internal Medicine at the Michael Reese Hospital (IL, USA). In 1992, he became a Fellow in Oncology at the Johns Hopkins Oncology Center (MD, USA), where he also obtained a masters degree in clinical investigation. He joined Duke University in 1996 and took up his current position in 1997. Dr Hurwitz is Clinical Director of the Duke Phase I Program. He also oversees clinical trials of new anticancer drugs, particularly anti-angiogenic agents, drug combinations and radiotherapy-containing regimens. He has a particular interest in gastrointestinal cancer and is the co-leader of the Duke Gastrointestinal Oncology Program. He was the lead investigator of the recently completed IFL–Bevacizumab study for metastatic colorectal cancer.